TITLE

Research Capsules

PUB. DATE
February 2007
SOURCE
Pharmaceutical Representative;Feb2007, Vol. 37 Issue 2, p15
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses several drugs researches in the U.S. A clinical investigation reveals that ruboxistaurin mesylate with trade name Arxxant from Eli Lily & Co. can significantly reduced vision loss in diabetic retinopathy patients. The study conducted by the National Hospice Outcomes Project shows that use of opioid can not hasten death in patients with advanced disease. Investigational dopamine agonist rotigotine from Schwarz Pharma was found to benefit Parkinson's disease patients.
ACCESSION #
23970927

 

Related Articles

  • Schwarz recalls Neupro Parkinson's treatment.  // Pharmacy Today;Apr2008, Vol. 14 Issue 4, p1 

    The article reports on the product recall made by Schwarz Pharma AG for its Neupro, a treatment for early-stage idiopathic Parkinson's disease in April 2008 in the U.S. The company made the recall which will start and end in April, due to the reports of rotigotine crystals that form in Neupro...

  • Schwarz launch orally dissolving Parkinson's drug.  // PharmaWatch: CNS;November 2004, Vol. 3 Issue 11, p9 

    Reports that the U.S. division of pharmaceutical firm Schwarz has launched Parkinson's treatment Parcopa. Description of the drug as a carbidopa-levodopa formulation that dissolves rapidly on the tongue; Approval of Parcopa by the U.S. Food and Drug Administration on August 27, 2004; Treatment...

  • Positive trial results for Schwarz's Parkinson's patch.  // PharmaWatch: CNS;November 2004, Vol. 3 Issue 11, p10 

    Reports on Schwarz Pharma's announcement that its Neupro patch significantly reduced "off" time in advanced Parksinson's disease patients when used as an adjunctive therapy. Details of the U.S. phase III clinical trial results; Application site reactions; Adverse events associated with the use...

  • New disintegrating tablets for Parkinson's disease.  // Drug Topics;9/13/2004, Vol. 148 Issue 17, p12 

    Carbidopa/levodopa (Parcopa, Schwarz Pharma) orally disintegrating tablets have been approved by the U.S. Food and Drug Administration for the treatment of symptoms of idiopathic Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the...

  • FDA approval given to Schwarz Pharma's Parkinson's drug. Pharma, Schwarz // PharmaWatch: CNS;October 2004, Vol. 3 Issue 10, p9 

    The article presents information on approval of Food and Drug Administration (FDA) approval to Schwarz Pharma AG's Prkinson's drug. Schwarz Pharma has received approval from the FDA to market Parcopa, an oral formulation of the Parkinson's disease drug, carbidopa-levodopa. Unlike conventional...

  • Schwarz Pharma: Neupro to improve patient convenience in Parkinson's.  // PharmaWatch: CNS;Jun2007, Vol. 6 Issue 6, p5 

    The article reports on the approval of Schwarz Pharma's Neupro by the U.S. Food and Drug Administration. The drug is a transdermal patch formulation of the dopamine agonist rotigotine for the treatment of early-stage Parkinson's disease. Neupro is designed for once-daily application, making the...

  • Schwarz Pharma: Neupro to improve patient convenience in Parkinson's.  // PharmaWatch: Monthly Review;Jun2007, Vol. 6 Issue 6, p14 

    The article reports on the approval given by the U.S. Food and Drug Administration (FDA) to Neupro of Schwarz Pharma AG, a transdermal patch formulation of the dopamine agonist rotigotine, for the treatment of early-stage Parkinson's disease (PD). It is stated that the approval of Neupro follows...

  • Pfizer. Investor's Business Daily // Investors Business Daily;3/24/2015, pA02 

    The article reports that the biopharmaceutical firms Pfizer and Eli Lilly will resume the phase 3 chronic pain test for tanezumab.

  • Adolor Pays $2M Up Front for Bowel Drug.  // Bioworld Week;9/28/2009, Vol. 17 Issue 39, p3 

    The article reports on the move of Adolor Corp. to purchase product and rights of opioid-induced bowel dysfunction (OBD) drug of Indianapolis-based Eli Lilly and Co. in Exton, Pennsylvania. It notes that the company purchased the product for 2 million dollars while the product rights was 70...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics